{"prompt": "['Date and version No: FUTUREGB_Protocol_V6.0_19Jan2022.doc:', 'The following stop-go criteria are proposed for the Trial Steering Committee (TSC) after 12 months of', 'recruitment:', 'actual recruitment after 12 months of recruitment', 'target = 80', '>80 participants', '65 - 80 participants', '<65 participants', 'recruitment rate', '0.6', '0.45', '0.37', '(per centre per month)', 'recruitment feasible', 'review recruitment strategies', 'recruitment not feasible', 'report to TSC', 'stop-go criteria', 'proceed with study', 'continue but modify and monitor', 'decision not to proceed', 'closely', 'The TSC and the funder would make the final decision to terminate the trial.', '11.8. Stopping rules', '11.8.1. Stage 1 (IDEAL study)', 'There are no formal stopping rules for this Stage of the study.', '11.8.2. Stage 2 (RCT)', 'Given the nature of the primary, and key secondary, outcomes and the planned study length, no formal', 'interim analyses with stopping guidelines are planned. An independent Data Safety and Monitoring', 'Committee (DSMC) will review the accumulating data at regular intervals and may recommend pausing', 'or stopping the trial in the event of safety concerns.', '11.9. The Level of Statistical Significance', 'All principal analyses will be performed at the 2-sided 5% significance level.', '11.10. Procedure for Accounting for Missing, Unused, and Spurious Data.', 'The procedure for handling spurious or missing data will be described in the Statistical Analysis Plan, and', 'the Data Monitoring Plan. The trial will attempt to collect data as completely as possible.', 'The main analysis will include participants for whom endpoint data are available, with other participants', 'being censored after their last available relevant outcome measure. Sensitivity analyses will examine the', 'effects of alternative assumptions about the missing data.', '11.11. Procedures for Reporting any Deviation(s) from the Original Statistical Plan', 'Any deviation(s) from the original statistical plan will be described and justified in the final report, should', 'these occur.', 'Clinical Research Protocol Template version 14.0', 'Page 43 of 65', 'C Copyright: The University of Oxford and Oxford University Hospitals NHS Foundation Trust 2018', 'CONFIDENTIAL']['Date and version No: FUTUREGB_Protocol_V6.0_19Jan2022.docr', '11.12. Health Economics Analysis', 'There are no health economic analyses to be undertaken as part of the trial.', '12. DATA MANAGEMENT', 'A data management and sharing plan will be produced for the trial in accordance with OCTRU Standard', 'Operating Procedures (SOPs), this will include reference to confidentiality, access and security', 'arrangements.', 'All data will be processed following the SOPs, which have been written in line with all applicable', 'regulatory requirements. All trial-specific documents, except for the signed consent form and follow-up', 'contact details, will refer to the participant with a unique study participant number/code and not by', 'name. All patient data will be stored securely in accordance with OCTRU SOPs All trial data will be stored', 'securely in offices only accessible by swipe card by the central coordinating team staff in Oxford, and', 'authorised personnel.', 'Data will be collected from participants and proxies via questionnaires and case report forms that will be', 'returned to the central trial office in Oxford, via post using a pre-addressed freepost envelope, or NHS', \"email as appropriate, or directly into an online secure database - the study's dedicated instance of\", 'REDCap. In addition, participant images will be stored within the cloud database Quentry (BrainLab AG).', 'As a third-party processor BrainLab will not receive any data that could identify participants.', 'Participant data will be stored and transported in accordance to SOPs. Upon completion of the trial, fully', 'de-identified research data may be shared with other organisations at the behest of the funder.', '12.1. Source Data', \"Source documents are where data are first recorded, and from which participants' CRF data are\", 'obtained. These include, but are not limited to, hospital records (from which medical history and', 'previous and concurrent medication may be summarised into the CRF), clinical and office charts,', 'laboratory and pharmacy records, scans, diaries, microfiches, radiographs, and correspondence.', 'CRF entries will be considered source data if the CRF is the site of the original recording (e.g. there is no', 'other written or electronic record of data). All documents will be stored safely in confidential conditions.', 'On all study-specific documents, other than the signed consent and follow-up contact details, the', 'participant and proxy will be referred to by the study participant/proxy number/code, not by name.', '12.2. Access to Data', 'Direct access will be granted to authorised representatives from the Sponsor, host institution and the', 'regulatory authorities to permit trial-related monitoring, audits and inspections.', 'Where data is submitted directly to the trial office, contemporaneous access by local research teams to', \"the online database will enable the local research teams at sites to download copies of their participants'\", 'data.', 'Clinical Research Protocol Template version 14.0', 'Page 44 of 65', 'C Copyright: The University of Oxford and Oxford University Hospitals NHS Foundation Trust 2018', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}